Merck EPS - Earnings per Share 2006-2018 | MRK

Merck annual and quarterly earnings per share history from 2006 to 2018. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Merck EPS for the quarter ending December 31, 2018 was $0.69, a 281.58% decline year-over-year.
  • Merck EPS for the twelve months ending December 31, 2018 was $2.32, a 166.67% increase year-over-year.
  • Merck 2018 annual EPS was $2.32, a 166.67% increase from 2017.
  • Merck 2017 annual EPS was $0.87, a 38.3% decline from 2016.
  • Merck 2016 annual EPS was $1.41, a 9.62% decline from 2015.
Merck Annual EPS
2018 $2.32
2017 $0.87
2016 $1.41
2015 $1.56
2014 $4.07
2013 $1.47
2012 $2.00
2011 $2.02
2010 $0.28
2009 $5.65
2008 $3.63
2007 $1.49
2006 $2.03
2005 $2.10
Merck Quarterly EPS
Q4 2018 $0.69
Q3 2018 $0.73
Q2 2018 $0.63
Q1 2018 $0.27
Q4 2017 $-0.38
Q3 2017 $-0.02
Q2 2017 $0.71
Q1 2017 $0.56
Q4 2016 $-0.20
Q3 2016 $0.78
Q2 2016 $0.43
Q1 2016 $0.40
Q4 2015 $0.35
Q3 2015 $0.64
Q2 2015 $0.24
Q1 2015 $0.33
Q4 2014 $2.51
Q3 2014 $0.31
Q2 2014 $0.68
Q1 2014 $0.57
Q4 2013 $0.27
Q3 2013 $0.38
Q2 2013 $0.30
Q1 2013 $0.52
Q4 2012 $0.30
Q3 2012 $0.56
Q2 2012 $0.58
Q1 2012 $0.56
Q4 2011 $0.48
Q3 2011 $0.55
Q2 2011 $0.65
Q1 2011 $0.34
Q4 2010 $-0.16
Q3 2010 $0.11
Q2 2010 $0.24
Q1 2010 $0.09
Q4 2009 $2.63
Q3 2009 $1.61
Q2 2009 $0.74
Q1 2009 $0.67
Q4 2008 $0.78
Q3 2008 $0.51
Q2 2008 $0.82
Q1 2008 $1.52
Q4 2007 $-0.76
Q3 2007 $0.70
Q2 2007 $0.77
Q1 2007 $0.78
Q4 2006 $0.22
Q3 2006 $0.43
Q2 2006 $0.69
Q1 2006 $0.69
Q4 2005 $0.50
Q3 2005 $0.65
Q2 2005 $0.33
Q1 2005 $0.62
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $223.649B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $370.509B 16.88
Pfizer (PFE) United States $252.104B 14.12
Novartis AG (NVS) Switzerland $216.355B 18.40
Eli Lilly (LLY) United States $132.855B 23.08
Novo Nordisk (NVO) Denmark $127.479B 20.62
AbbVie (ABBV) United States $119.836B 10.27
Sanofi (SNY) France $113.942B 14.06
AstraZeneca (AZN) United Kingdom $108.788B 12.41
GlaxoSmithKline (GSK) United Kingdom $102.300B 13.43
Bristol-Myers Squibb (BMY) United States $79.871B 12.29